Fennec Pharmaceuticals (TSX:FRX) FFO


TSX:FRX Fennec Pharmaceuticals Inc TSX:FRX
53 GF Score
Price C$15.24
GF Value C$14.13
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Fennec Pharmaceuticals FFO?

FFO (Funds from operations) only applies to REITs.

TSX:FRX
53GF Score
Fennec Pharmaceuticals Inc TSX:FRX
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Fennec Pharmaceuticals (TSX:FRX) Overvalued in 2026?

Based on GuruFocus' analysis, Fennec Pharmaceuticals stock appears to be overvalued. The current stock price of C$15.24 is trading 7.9% above its estimated GF Value™ of C$14.13. GuruFocus considers Fennec Pharmaceuticals to be Fairly Valued.

Key valuation signals for TSX:FRX:

  • FFO:
  • GF Value™: C$14.13 vs. price of C$15.24 (7.9% above fair value)
  • GF Score™: 53/100 with 2 warning signs

No single metric tells the full story. See the TSX:FRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Fennec Pharmaceuticals Business Description

Other Exchanges FENC:USARV41:Germany
Address 68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
53GF Score

Get the complete analysis for TSX:FRX

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$15.24
Price
C$14.13
GF Value